Aptose Biosciences INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Bleichroeder LP and affiliates report a passive 1.61% beneficial ownership in Aptose Biosciences Inc. common shares.
Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have jointly filed an amended Schedule 13G, reporting a passive beneficial ownership of 6.3% in Aptose Biosciences Inc.'s common shares.
Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has filed an amended Schedule 13G disclosing a 7.5% beneficial ownership stake in Aptose Biosciences Inc.
Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have disclosed a 6.2% beneficial ownership stake in Aptose Biosciences Inc. common shares through an amended Schedule 13G filing.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Aptose Biosciences Inc.'s common shares as of December 31, 2024.
Bleichroeder LP and Bleichroeder Holdings LLC have disclosed a passive 6.2% beneficial ownership stake in Aptose Biosciences Inc. as of December 31, 2024.